- Home
- CGNT vs PHAR Comparison
CGNT vs PHAR Comparison
Compare CGNT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PHAR
- Stock Information
- Founded
- CGNT 2020
- PHAR 1988
- Country
- CGNT Israel
- PHAR Netherlands
- Employees
- CGNT N/A
- PHAR N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PHAR Health Care
- Exchange
- CGNT Nasdaq
- PHAR Nasdaq
- Market Cap
- CGNT 617.3M
- PHAR 951.7M
- IPO Year
- CGNT N/A
- PHAR N/A
- Fundamental
- Price
- CGNT $8.35
- PHAR $13.10
- Analyst Decision
- CGNT Buy
- PHAR Strong Buy
- Analyst Count
- CGNT 2
- PHAR 3
- Target Price
- CGNT $14.00
- PHAR $30.00
- AVG Volume (30 Days)
- CGNT 284.4K
- PHAR 10.8K
- Earning Date
- CGNT 12-10-2025
- PHAR 11-06-2025
- Dividend Yield
- CGNT N/A
- PHAR N/A
- EPS Growth
- CGNT N/A
- PHAR N/A
- EPS
- CGNT N/A
- PHAR N/A
- Revenue
- CGNT $376,566,000.00
- PHAR $339,836,000.00
- Revenue This Year
- CGNT $15.30
- PHAR $17.70
- Revenue Next Year
- CGNT $11.30
- PHAR $12.25
- P/E Ratio
- CGNT N/A
- PHAR N/A
- Revenue Growth
- CGNT 14.04
- PHAR 22.44
- 52 Week Low
- CGNT $6.38
- PHAR $7.31
- 52 Week High
- CGNT $11.66
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- CGNT 49.93
- PHAR 42.79
- Support Level
- CGNT $7.82
- PHAR $13.08
- Resistance Level
- CGNT $8.59
- PHAR $14.10
- Average True Range (ATR)
- CGNT 0.18
- PHAR 0.52
- MACD
- CGNT 0.04
- PHAR -0.15
- Stochastic Oscillator
- CGNT 68.83
- PHAR 3.93
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.